|
|
Our Fall $200,000 Match Challenge starts today. Your gift can make 2X the impact.
|
|
|
|
|
Dear Friend,
Summer is ending, but the fight against Alzheimer's disease continues. You can help get fall off to a great start by making your first gift during our brand-new Fall $200,000 Match Challenge.
When you do, you can DOUBLE your impact and make a difference for people affected by this terrible disease.
For this exciting challenge, longtime supporters Dick and Marianne Kipper have graciously pledged to match every dollar we receive until October 31 — up to $200,000.
That's why I'm turning to you today, friend. Please make your first gift now, while it can go 2X as far in our fight to end Alzheimer's.
The Kippers are longtime members of our Zenith Society, and their gift will go toward advancing Alzheimer's disease research. Your first donation will help provide care and support and accelerate research.
But in order to achieve this challenge, we must raise the same amount — $200,000 — by the deadline to unlock these matching funds. Please show your support today, while your first gift can go 2X as far to make a meaningful difference in so many more lives.
| Join our Fall $200,000 Match Challenge and see how far your first gift can go. |




|
Friend, this special opportunity has come at an important time. Right now, more than 6 million Americans are living with Alzheimer's — and that number is rising. This cruel disease has a big impact on every part of life. Many of us have seen firsthand how it devastates families and communities.
But there is encouraging news: With the support of friends like you, we are getting closer to a cure. And right now, your first gift can be matched 2X.
New Food and Drug Administration-approved treatments are now available. These treatments help people living with early Alzheimer's by slowing down the disease's progression. This can give people more time to spend with family and do the things they love. Even better? More encouraging breakthroughs are in the research pipeline.
Real progress is happening — we can't stop now.
However, these treatments are not cures, and they are not for everyone. There are also barriers to access that we are working relentlessly to bring down. We won't rest until everyone living with Alzheimer's — at any stage — can get the treatment and care and support they need and deserve.
We must confront this national public health crisis head-on. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.
The strong interest you've taken in our efforts tells me you believe in this fight. Now is the time to step up for the millions of Americans who are counting on us to keep our progress going. Please consider making your first gift today — while it can go TWICE as far.
Please be sure to show your support while your first gift can still be matched 2X. Together, we can make a difference that moves us closer to our vision of a world without Alzheimer's and all other dementia. Thank you.
Sincerely,

Donna McCullough
Chief Mission and Field Operations Officer
P.S. Don't miss this opportunity to make 2X the impact in our fight to end Alzheimer's. Join our Fall $200,000 Match Challenge, while your first gift can go TWICE as far.
|
|
Your donation will strengthen our efforts to advance Alzheimer's care, support and research. From face-to-face support to online education programs and promising global research initiatives, your gift makes a difference in the lives of all those affected by Alzheimer's and other dementias in your community and across the world. Thank you for your continued support.
Alzheimer's Association Home Office, 225 N. Michigan Ave., Fl. 17, Chicago, IL 60601
© 2023 Alzheimer's Association. All rights reserved.
800.272.3900 | alz.org® | Donate
Please add [email protected] to your address book to ensure you receive all future emails.
Having trouble reading this email?
View it in your browser
View your email preferences or unsubscribe.
|
|
|
|